3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
65
Neoplasm Metastasis
11
Advanced Breast Cancer
5
Neoplasms
4
Recurrence
2
Multiple Endocrine Neoplasia Type 1
2
Locally Advanced (Inoperable) or Metastatic Breast Cancer
2
Hereditary Sensory and Autonomic Neuropathies
2
Unilateral Breast Neoplasms
1
Neoplasms by Site
1
HR-positive, HER2-negative Breast Neoplasms
1
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
1
Disease Progression
1
Carcinoma, Lobular
1
Carcinoma, Ductal, Breast
1
Breast Neoplasm Female
1
Breast Diseases
1
Interventions
Lenalidomide
3
capivasertib
2
Bortezomib
2
tivozanib
1
Zoledronic Acid
1
Vitamin D
1
Temozolomide
1
Radiotherapy
1
Nivolumab
1
Gemcitabine
1
Fulvestrant
1
Etoposide
1
Dexamethasone
1
Cisplatin
1
Carboplatin
1
Calcium Dobesilate
1
Calcium
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Disease Progression
×
Fulvestrant
×
Clear all
NCT06635447
2026-03-27
CAPItrue
AstraZeneca
Phase 3
Active not recruiting
258 enrolled